Business Insider

Lilly's Emgality™ (galcanezumab-gnlm) Receives U.S. FDA Approval for the Preventive Treatment of Migraine in Adults

INDIANAPOLIS, Sept. 27, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality™ (galcanezumab-gnlm) 120 mg ...
Nasdaq

FDA Approves Emgality® (galcanezumab-gnlm) as the First and Only Medication for the Treatment of Episodic Cluster Headache that Reduces the Frequency of Attacks

INDIANAPOLIS, June 4, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality ® (galcanezumab-gnlm) injection (300 ...
MarketWatch

Eli Lilly says FDA has approved new migraine drug Emgality

Eli Lilly and Company [s:lly] said late Thursday that the U.S. Food and Drug Administration has approved its drug Emgality for the preventive treatment of migraine in adults. Emgality is delivered via ...
Healio

FDA grants headache drug priority review

Please provide your email address to receive an email when new articles are posted on . The FDA recently granted priority review to the supplemental Biologics License Application for Emgality ...
FiercePharma

Lilly’s Emgality nabs third-to-market migraine nod but aims to be 'treatment of choice' in CGRP

Lilly will provide 12 months of Emgality to patients for free under an access program, an executive said. (Eli Lilly) Eli Lilly may not be first to the market with its next-gen migraine drug Emgality, ...
FiercePharma

NICE's thumbs-up on Lilly's migraine med Emgality leaves rivals from Novartis and Teva in the dust

NICE cited data showing that more people taking Emgality who suffer from episodic migraines had a 50% drop in average migraine days per month when compared to placebo. (Eli Lilly) () England's drug ...
MarketWatch

Eli Lilly's Emgality gets FDA approval for episodic cluster headaches

Eli Lilly & Co. said Wednesday Emgality injection was approved by the U.S. Food and Drug Administration for the treatment of episodic cluster headache in adults. Lilly said Emgality is the first and ...
Monthly Prescribing Reference

Migraine Prevention Treatment Emgality Gets FDA Approval

The approval was based on data from 3 randomized, double-blind, placebo-controlled trials (EVOLVE-1, EVOLVE-2, REGAIN) in patients with either episodic or chronic migraine. The Food and Drug ...
Healio

FDA approves Emgality for migraine prevention

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Emgality, a once-monthly, self-administered, subcutaneous injection, for the preventive ...
KRQE Blogs

First-Of-Its-Kind Head-to-Head Clinical Trial Reaffirms the Efficacy of Emgality in Episodic Migraine Prevention

The CHALLENGE-MIG study demonstrates Lilly's commitment to migraine research and results underscore that people living with episodic migraine deserve broad access to effective treatments "These ...
Nasdaq

Lilly's Emgality Gets FDA Priority Review for Cluster Headache

Eli Lilly and CompanyLLY announced that the FDA has granted a priority review to the supplemental biologics license application (sBLA) for its calcitonin gene-related peptide (CGRP) antibody, Emgality ...